{"id":"W3213641350","doi":"10.1182/blood-2021-154195","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Atezolizumab; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Rituximab; Internal medicine; Oncology; Bendamustine; Alemtuzumab; Leukemia; Pembrolizumab; Cancer; Immunotherapy; Lymphoma; Transplantation","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003603696,0.0002857824,0.0005942876,0.000200239,0.0002281129,0.0004658379,0.0002775074,0.0004369748,0.003984796],"category_scores_gemma":[0.0003346258,0.0001501585,0.0004701889,0.0002026352,0.0001950285,0.0002944334,0.000212456,0.001105305,0.0004471447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006103032,"about_ca_system_score_gemma":0.0008402822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005122154,"about_ca_topic_score_gemma":0.003489693,"domain_scores_codex":[0.9998673,0.00004216305,0.00001167156,0.00002671029,0.0000211261,0.00003104391],"domain_scores_gemma":[0.9998206,0.00003359996,0.00004418157,0.0000066603,0.00001048938,0.00008441538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2046486,0.0161667,0.05024965,0.003478243,0.001296331,0.001047127,0.0003338376,0.002574685,0.06818525,0.0008041214,0.01613943,0.635076],"study_design_scores_gemma":[0.3097252,0.430236,0.1422984,0.00103948,0.002831835,0.006311489,0.0002808222,0.00436137,0.02674082,0.00097201,0.07511004,0.00009273839],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658809,0.02269589,0.0005629201,0.001153734,0.0001608218,0.001131758,0.0009804209,0.0001181892,0.007315335],"genre_scores_gemma":[0.9914591,0.003500801,0.0009742157,0.0006040768,0.00008681289,0.0003954359,0.0007500494,0.000006223013,0.002223132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003984796,"threshold_uncertainty_score":0.01333052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01772876279167776,"score_gpt":0.2684535897771648,"score_spread":0.250724826985487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}